Hereditary Myelodysplastic Syndrome (MDS) / Acute Myeloid Leukemia (AML) Panel
Use
This test is designed for individuals who have a clinical or suspected diagnosis of hereditary myelodysplastic syndrome or acute myeloid leukemia. The panel aims to identify genetic variants that may inform diagnosis, prognosis, and potential therapeutic opportunities. It encompasses 12 genes which are relevant to these hematologic conditions, allowing for a comprehensive analysis of potential hereditary factors.
Special Instructions
Not provided.
Limitations
Not all genetic variants are detectable with this panel, as it is limited to the specified 12 genes. Variants outside these loci will not be assessed. Technical limitations include the inability to detect certain types of mutations such as large deletions or duplications without high-confidence CNV analysis, which is an optional add-on. False negatives may occur due to the nature of the sequencing or low variant allele fractions.
New York Approved
Methodology
NGS (CGP)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided